A bio-immuno assay for measuring human vWF Collagen Binding Activity



von Willebrand Factor (VWF) is of bigg importance in primary haemostasis and one of its many functions is supporting the platelets to bind at sub-endothelial collagen of a lesioned vessel wall. The Collagen Binding Assay (CBA) serves as a determination of the VWF-binding-capacities to collagen and can be used as a part of von Willebrand’s Disease (vWD) investigation.

The vWF:CBA assay is based on the ability of vWF (High Molecular Weight forms) to bind collagen. Thus useful to reflect the “true” physiological activity of vWF, and the better characterize the vWD type. The assay can also be used as a disease marker or indicator for cardiovascular diseases when used in the assessment of clinical samples.

Ordering information

Product Name Reference Package


Other related products

Product Name Assay principle Reference Package
ZYMUTESTTM vWF     (CE-IVD) An enzyme-immuno-assay for measuring human vWF in plasma, or in any fluid where vWF can be present. RK030A 96 tests
LIAPHENTM vWF:Ag (CE-IVD) An Immunoturbidimetric assay for in vitro quantitative determination of von Willebrand Factor Antigen (vWF:Ag) on human citrated plasma, using a manuel of automated method. Reagents are in the liquid presentation, ready to use.  120206 R1: 4 x 5 ml

R2: 4 x 6 ml

 BIOPHENTM  FVIII:C  (CE-IVD)  A chromogenic assay for measuring the factor VIII:C activity in human plasma or in factor VIII:C concentrates, using a chromogenic method, manual or automated. 221402


2 x 2,5 ml

2 x 6 ml

 FVIII:C Deficient Plasma (CE-IVD)  A clotting assay for the measurement of Factor VIII:C activity in human citrated plasma, to be used in the presence of cephalin, activator and calcium (aPTT reagent).  DP040A


1 x 1 ml

6 x 1 ml



  1.  Luo et al. von Willebrand Factor: more than a regulator of hemostasis and thrombosis. Acta Haematol, 2012, 128:158-169.
  2. Peyvandi et al. Role of von Willebrand Factor in the haemostasis. Blood Transfus, 2011, 9 suppl 2:s3-s8.
  3. Sadler JE(1), Budde UEikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, et al. Update on the pathopphysiology and the classification of von Willebrand disease: a report of the Subcommitte on von Willebrand Factor. J Thromp Haemost 2006 Oct;4(10):2103-2114
  4. favaloro EJ. new developments in the diagnosis and treatment of von Willebrand disease. Clin. Invest. 2012 2(8), 781-795